Tabbe 2. Evidence table for therapeutic trials.
| Reference | Study features | Treatment groups | Endpoints | Serious adverse events | |
|
Liu 2019 (14) |
• 122 patients •2010 – 2013 •Follow-up: 6 months |
Chinese herbal medicine (n = 61) 4 weeks Antibiotics (n = 61) 4 weeks |
Chinese herbal medicine vs. antibiotics | No clinically relevant side effects in either group | |
|
Symptom improvement • ≥=95% symptomatic improvement: 31% (19/61) vs. 30% (18/61) • ≥=70% symptomatic improvement: 48% (29/61) vs. 26% (16/61); p<0.05 • ≥=30% symptomatic improvement: 18% (11/61) vs. 39% (24/61); p<0.05. • <30% symptomatic improvement or no response: 3% (2/61) vs. 5% (3/61) |
Treatment efficacy: 90% (55/61) vs. 82% (50/61) rUTI: 13% (8/61) vs. 20% (12/61) rUTI in cured patients: 9% (5/55) vs. 14% (7/50) |
||||
|
Cai 2018 (23) |
•93 patients •2017 •Follow-up: 3 months |
400 mg L-methionine, 100 mg Hibiscus sabdariffa, 100 mg Boswellia serrata (n = 46) one week Antibiotics (n = 47) Short-term antibiotic therapy (according to the EAU guideline) |
Combined preparation vs. antibiotics |
Combined preparation: No side effects Antibiotics: 14.9% (7/47) discontinuation of drug because of drug-related adverse events. |
|
|
Clinical Improvement: •30 days: 96% (44/46) vs. 100% (47/47) •90 days: 96% (44/46) vs. 96% (45/47) |
Quality of life: •Baseline: 94.3 vs. 94.5 •30 days: 98.5 vs. 98.7 •90 days: 99.1 vs. 98.1 p<0.003 |
||||
EAU: European Association of Urology, n: number of patients in trial arm, UTI: urinary tract infection, rUTI: recurrent urinary tract infection.